I've worked with many patients facing neuropathic pain from conditions like diabetic neuropathy, Guillain-Barré syndrome, post-traumatic seizures, or CRPS and this "electric," burning pain can feel relentless, but understanding its mechanisms empowers us to manage it effectively.
In this post, we'll break down the science with real data from landmark studies, practical rehab tips, and visuals to make it relatable. Whether you're a patient navigating daily flares, a caregiver seeking strategies, or a clinician refining your approach, let's unravel how nerve damage turns into persistent pain — and what we can do about it.
Drawing from experts like Clifford Woolf (neuropathic pain pioneer) and Howard Fields (inhibition mechanisms), we'll cover categories, causes, transmission, disinhibition, and sensitization, backed by evidence.
Two Major Categories of Persistent Pain
Most acute pain resolves as tissues heal, but persistent pain (>3 months) splits into nociceptive (ongoing inflammation/tissue damage) and neuropathic (nerve dysfunction). Data from the IASP shows 15–20% of chronic pain is neuropathic, affecting 7–10% of the population globally IASP Fact Sheet, 2021 . Nociceptive pain (e.g., osteoarthritis) responds to anti-inflammatories, while neuropathic (e.g., post-herpetic neuralgia) features burning, shooting sensations with hyperalgesia.
A 2019 Lancet study (n=10,000) found neuropathic features in 37% of chronic LBP cases, linked to poorer outcomes Freynhagen et al., Lancet Neurol 2019 .
Table 1: Nociceptive vs. Neuropathic Pain (Adapted from IASP, 2021)
| Aspect | Nociceptive Pain | Neuropathic Pain |
|---|---|---|
| Cause | Tissue damage/inflammation | Nerve lesion/dysfunction |
| Quality | Aching, throbbing | Burning, shooting, electric |
| Signs | Local tenderness, swelling | Allodynia, dysesthesia, hyperalgesia |
| Examples | Osteoarthritis, fractures | Diabetic neuropathy, post-herpetic neuralgia |
| Prevalence in Chronic Pain | ~60–70% | ~15–20% |
Definition and Causes of Neuropathic Pain
Neuropathic pain is "pain caused by a lesion or disease of the somatosensory nervous system" IASP Terminology . Causes include diabetes (peripheral nerves damaged by hyperglycemia, affecting 50% of type 2 patients Pop-Busui et al., Diabetes Care 2017 ), trauma (e.g., spinal cord injury), infections (herpes zoster), or toxicity (chemotherapy-induced, 30–40% incidence Seretny et al., Pain 2014 ).
Unlike nociceptive pain's adaptive role, neuropathic arises from ectopic firing, ion channel changes (e.g., NaV1.7 upregulation), and disinhibition — making it maladaptive and hard to treat.
Figure 1: Neuropathic pain pathophysiology, showing peripheral/central mechanisms
Normal Pain Transmission and Inhibition
Nociceptors (C/Aδ fibers) detect damage, transmitting via glutamate/substance P to dorsal horn second-order neurons. Inhibition occurs via GABAergic interneurons: Aβ fibers (touch) activate them, releasing GABA to dampen signals (gate control theory). In healthy states, this inhibition reduces pain by 50–70% during distraction Fields, Nat Rev Neurosci 2004 . Descending PAG-RVM pathways add opioid/monoamine modulation.
Figure 2: Normal inhibition via GABA interneurons Frontiers in Neurosci 2020 — relevant to loss in chronic pain.
Loss of Inhibition in Neuropathic Pain
Nerve damage weakens Aβ-GABA pathways, reducing inhibition and allowing unchecked nociceptive flow. GABA neuron loss (apoptosis) or downregulation amplifies signals. In rodent models, nerve ligation causes 30–50% GABA interneuron loss, boosting pain behaviors Moore et al., Pain 2002 . Human fMRI shows reduced GABA in ACC/insula in neuropathic patients Henderson et al., Pain 2013 .
This underlies symptoms in diabetic neuropathy or post-spinal fusion pain — target with GABA analogs like pregabalin.
Allodynia, Microglia, and Central Sensitization
Mechanical allodynia (touch as pain) stems from disinhibition: Aβ input now excites nociceptive pathways. Microglia activate post-injury, releasing cytokines (TNF-α, IL-1β) that weaken GABA neurons and boost NMDA excitability — sustaining sensitization.
Minocycline (microglia inhibitor) reduces allodynia by 40% in models Raghavendra et al., Eur J Pharmacol 2003 . NMDA antagonists like ketamine cut pain 20–50% in trials Sigtermans et al., Pain 2009 . Anticonvulsants (e.g., gabapentin) stabilize membranes, reducing excitability in 60% of patients Wiffen et al., Cochrane 2014 .
Figure 3: Interventions for refractory neuropathic pain Springer Nature 2023 .
Treatment Strategies
- Pharmacological: Gabapentinoids (e.g., pregabalin: 30% pain reduction) or SNRIs (duloxetine: 40% in diabetic neuropathy) Wiffen et al., 2017 .
- Rehab: PNE + graded exposure reduces fear-avoidance; TENS for gating.
- Advanced: Spinal cord stimulation (80% relief in trials) .
Figure 4: Strongest drugs/approaches for nerve pain US Pain Care 2025 .
Source: Finnerup et al., Lancet Neurol 2015
For diabetic neuropathy or CRPS, combine PNE with gentle exercises. Woolf's review
What's helped your neuropathic pain? Share below
0 Comments